BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has signed a letter of intent establishing ICON (ICON; NASDAQ: ICLR) as the global clinical research organization (CRO) for the Company’s ongoing pivotal phase II/III clinical trial for MBP8298 for the treatment of multiple sclerosis.
